Idera Pharmaceuticals EBIT

Idera Pharmaceuticals (IDRA) currently reports a EBIT of $-48M as of March 2023. That compares with $-22M in the prior-year period — down 118.3% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Idera Pharmaceuticals's EBIT history and peer comparisons.

Idera Pharmaceuticals's EBIT decreased from $-22M to $-48M — a 118.3% year-over-year decrease (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Idera Pharmaceuticals's EBIT of $-48M is lower than the Healthcare sector average of $22B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Idera Pharmaceuticals reported $-48M in EBIT as of March 2023. That compares with $-22M in the prior-year period — down 118.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-48M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Idera Pharmaceuticals, and consider following IDRA for alerts when major investors trade the stock.